# US 12,109,206 B2 · Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,206 B2
- Document ID: US12109206B2
- Status: Granted
- Kind: B2
- Application number: 17/872,575
- Filed: 2022-07-25
- Published: 2022-11-17
- Granted: 2024-10-08
- Earliest claimed: 2015-06-10
- Assignees: Elysium Health, Inc.
- Applicants: Elysium Health, Inc.
- Inventors: Eric A. Marcotulli; Daniel A. Alminana; Paul M. Bowen
- Web page: https://patentgrep.com/patent/US12109206B2

## CPC

- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 8/368: with carboxyl groups directly bound to carbon atoms of aromatic rings
- A61K 8/675: {Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde (tocopheryl nicotinate A61K8/678)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/09: having two or more such linkages
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61P 17/00: Drugs for dermatological disorders
- A61Q 19/004: {Aftersun preparations}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions containing a combination of nicotinamide riboside and pterostilbene for treating skin disorders, and methods of treating skin disorders using these compositions and their equivalents are described. The skin disorders that are treated using these compositions or methods include sun exposure-related skin disorders, inflammatory skin disorders, autoimmune disease-related skin disorders and cancer-related skin disorders. In one embodiment, the compositions containing a combination of nicotinamide riboside and pterostilbene are prepared as oral formulations.

## Claims

### Claim 1

A method of treating sunburn in a patient in need thereof comprising orally administering a combination of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene, wherein the therapeutically effective amount of nicotinamide riboside is 250 mg per day, the therapeutically effective amount of pterostilbene is 50 mg per day.

### Claim 2 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of nicotinamide riboside and the therapeutically effective amount of pterostilbene is administered in the same composition.

### Claim 3 (depends on 2)

The method of claim 2, wherein the composition comprises a pharmaceutically acceptable excipient.

### Claim 4 (depends on 3)

The method of claim 3, wherein the pharmaceutically acceptable excipient is selected from the group consisting of microcrystalline cellulose, hypromellose, vegetable magnesium stearate, olive oil, gelatin, glycerin, purified water, beeswax yellow, sunflower lecithin, silicon dioxide, titanium dioxide, F. D. & C Blue 1 and F. D. & C Red 4.

### Claim 5

A method of treating lentigines or age spots in a patient in need thereof comprising orally administering a combination of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene, wherein the therapeutically effective amount of nicotinamide riboside is 250 mg per day, the therapeutically effective amount of pterostilbene is 50 mg per day.

### Claim 6

A method of treating skin cancer in a patient in need thereof comprising orally administering a combination of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene, wherein the therapeutically effective amount of nicotinamide riboside is 250 mg per day, the therapeutically effective amount of pterostilbene is 50 mg per day.